CENTESSA PHARMACEUTICALS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.45 USD | -0.59% |
|
+4.57% | +6.41% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 961M |
|---|---|---|---|---|---|
| Net income 2024 * | -182M | Net income 2025 * | -206M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 207M | Net cash position 2025 * | 168M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-5.48
x | P/E ratio 2025 * |
-5.2
x | Employees | 77 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.4% |
More Fundamentals
* Assessed data
More news
Latest transcript on Centessa Pharmaceuticals plc
More recommendations
More press releases
More news
| 1 day | -0.35% | ||
| 1 week | +4.57% | ||
| Current month | -1.85% | ||
| 1 month | -8.43% | ||
| 3 months | -24.17% | ||
| 6 months | +19.30% | ||
| Current year | +6.41% |
1 week
7.75
8.96
1 month
7.759.71
Current year
6.6512.45
1 year
4.3412.45
3 years
2.8926.90
5 years
2.8926.90
10 years
2.8926.90
| Managers | Title | Age | Since |
|---|---|---|---|
Saurabh Saha
CEO | Chief Executive Officer | 47 | 20-12-31 |
| Director of Finance/CFO | 53 | 21-02-28 | |
Ellie Im
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 61 | 21-02-22 | |
| Chairman | 54 | 20-10-31 | |
Brett Zbar
BRD | Director/Board Member | 51 | 20-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-04 | 8.45 | -0.59% | 195 610 |
| 24-06-03 | 8.5 | -1.51% | 414,363 |
| 24-05-31 | 8.63 | +6.28% | 165,406 |
| 24-05-30 | 8.12 | +1.00% | 62,414 |
| 24-05-29 | 8.04 | -0.74% | 124,098 |
Delayed Quote Nasdaq, June 04, 2024 at 03:59 pm EDT
More quotes
Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
Calendar
2024-06-06
- Jefferies Global Healthcare Conference
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
8.5
USD
Average target price
13.6
USD
Spread / Average Target
+60.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.41% | 961M | |
| +46.19% | 56.65B | |
| -6.14% | 39.44B | |
| +39.19% | 39.03B | |
| -6.65% | 26.86B | |
| +12.33% | 26.75B | |
| -21.78% | 19.03B | |
| -0.35% | 12.28B | |
| +24.18% | 12.26B | |
| +28.38% | 12.04B |
- Stock Market
- Equities
- CNTA Stock
